PMID- 31456159
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2509-4254 (Electronic)
IS  - 2509-4262 (Print)
IS  - 2509-4262 (Linking)
VI  - 4
IP  - 2
DP  - 2020 Jun
TI  - Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer 
      in a Mexican Population: A Chart Review.
PG  - 381-388
LID - 10.1007/s41669-019-00174-x [doi]
AB  - BACKGROUND: The available evidence regarding the clinical characteristics, 
      treatment patterns, adverse events (AEs), and costs of treating patients with 
      stage IV non-small cell lung cancer (NSCLC) in Mexico is scarce. OBJECTIVE: Our 
      objective was to describe the clinical characteristics, treatment patterns, and 
      direct costs associated with Mexican patients diagnosed with stage IV NSCLC who 
      had completed two or more lines of systemic antineoplastic treatment. METHODS: A 
      multicenter retrospective cohort study was designed to collect data from the 
      medical records of patients treated at tertiary-level public hospitals in Mexico 
      (multicenter chart review). We calculated costs from the viewpoint of payers 
      based on data regarding therapy and service utilization. RESULTS: A total of 115 
      patients were included. Median patient age was 61 years (interquartile range 
      [IQR] 52.4-68.5), and 51.3% were female. The most common NSCLC type was 
      non-squamous (92.2%), and the typical histology was adenocarcinoma (88.7%). All 
      patients received first- and second-line therapy: 54.78% completed a third-line, 
      27.82% a fourth-line, 7.82% a fifth-line, 2.6% a sixth-line, and 1.7% a 
      seventh-line active therapy. Carboplatin was the most frequently used therapy 
      (28.6%) followed by docetaxel (23.3%), nivolumab (16.7%), and irinotecan (13.3%). 
      AEs occurred in 53% of the patients and none was fatal. In total, 59 patients 
      (51.3%) required hospitalization during the observation period. The median cost 
      per patient was $US7039.40, with a minimum of $US628.30 and a maximum of 
      $US3,557,364.20. Median overall survival of the cohort was 12 months (95% 
      confidence interval 9.8-14.1). CONCLUSIONS: In Mexico, NSCLC is usually diagnosed 
      at stage IV. This study shows considerable variation in chemotherapy regimens, 
      leading to a wide range in treatment cost. The understanding of NSCLC treatment 
      patterns in Mexico will help to identify and address unmet needs.
FAU - Alatorre, Jorge Arturo
AU  - Alatorre JA
AD  - National Institute of Respiratory Diseases, Mexico City, Mexico.
FAU - Campos-Gomez, Saul
AU  - Campos-Gomez S
AD  - Department of Medical Oncology, State Oncology Center, Social Security Institute 
      of the State of Mexico and Municipalities, Mexico City, State of Mexico, Mexico.
FAU - De la Mora, Emmanuel
AU  - De la Mora E
AD  - Jalisco Cancer Institute, Jalisco, Mexico.
FAU - Novick, Diego
AU  - Novick D
AD  - Eli Lilly and Company, Surrey, UK. novick_diego@lilly.com.
FAU - Cruz, Angelica
AU  - Cruz A
AD  - Eli Lilly and Company, Mexico City, Mexico.
FAU - Iglesias-Chiesa, Jimena Maria
AU  - Iglesias-Chiesa JM
AD  - ZEED Pharmaceutical Solutions, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacoecon Open
JT  - PharmacoEconomics - open
JID - 101700780
PMC - PMC7248136
COIS- Jorge Arturo Alatorre has received professional fees for acting as a speaker and 
      scientific advisor for Eli Lilly. Saul Campos And Emmanuel De la Mora have no 
      conflicts of interest that are directly relevant to the content of this article. 
      Diego Novick and Angelica Cruz are employees of Eli Lilly and Company. Jimena 
      Maria Iglesias-Chiesa has received professional fees to conduct this study for 
      Eli Lilly and Company.
EDAT- 2019/08/29 06:00
MHDA- 2019/08/29 06:01
PMCR- 2019/08/27
CRDT- 2019/08/29 06:00
PHST- 2019/08/29 06:00 [pubmed]
PHST- 2019/08/29 06:01 [medline]
PHST- 2019/08/29 06:00 [entrez]
PHST- 2019/08/27 00:00 [pmc-release]
AID - 10.1007/s41669-019-00174-x [pii]
AID - 174 [pii]
AID - 10.1007/s41669-019-00174-x [doi]
PST - ppublish
SO  - Pharmacoecon Open. 2020 Jun;4(2):381-388. doi: 10.1007/s41669-019-00174-x.